Low-grade gliomas

被引：2
作者：
Schiff, David [1 ]
机构：
[1] Univ Virginia Hlth Syst, Neurooncol Ctr, Charlottesville, VA 22903 USA
来源：
JOURNAL OF NEUROSURGERY | 2011年 / 115卷 / 05期
关键词：
TEMOZOLOMIDE; RADIOTHERAPY; MANAGEMENT; MUTATIONS; SURVIVAL; ADULTS; IDH1;
D O I：
10.3171/2011.4.JNS11521
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：945 / 947
页数：3
相关论文
共 20 条
  • [1] *AM ASS NEURL SURG, 1998, NEUROSURG FOCUS, V4, pE10
  • [2] Update on molecular findings, management and outcome in low-grade gliomas
    Bourne, T. David
    Schiff, David
    [J]. NATURE REVIEWS NEUROLOGY, 2010, 6 (12) : 695 - 701
  • [3] Preoperative prognostic classification system for hemispheric low-grade gliomas in adults
    Chang, Edward F.
    Smith, Justin S.
    Chang, Susan M.
    Lamborn, Kathleen R.
    Prados, Michael D.
    Butowski, Nicholas
    Barbaro, Nicholas M.
    Parsa, Andrew T.
    Berger, Mitchel S.
    McDermott, Michael M.
    [J]. JOURNAL OF NEUROSURGERY, 2008, 109 (05) : 817 - 824
  • [4] Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up
    Douw, Linda
    Klein, Martin
    Fagel, Selene S. A. A.
    van den Heuvel, Josje
    Taphoorn, Martin J. B.
    Aaronson, Neil K.
    Postma, Tjeerd J.
    Vandertop, W. Peter
    Mooij, Jacob J.
    Boerman, Rudolf H.
    Beute, Guus N.
    Sluimer, Jasper D.
    Slotman, Ben J.
    Reijneveld, Jaap C.
    Heimans, Jan J.
    [J]. LANCET NEUROLOGY, 2009, 8 (09) : 810 - 818
  • [5] IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide
    Dubbink, H. J.
    Taal, W.
    van Marion, R.
    Kros, J. M.
    van Heuvel, I.
    Bromberg, J. E.
    Zonnenberg, B. A.
    Zonnenberg, C. B. L.
    Postma, T. J.
    Gijtenbeek, J. M. M.
    Boogerd, W.
    Groenendijk, F. H.
    Smitt, P. A. E. Sillevis
    Dinjens, W. N. M.
    van den Bent, M. J.
    [J]. NEUROLOGY, 2009, 73 (21) : 1792 - 1795
  • [6] MGMT gene silencing and benefit from temozolomide in glioblastoma
    Hegi, ME
    Diserens, A
    Gorlia, T
    Hamou, M
    de Tribolet, N
    Weller, M
    Kros, JM
    Hainfellner, JA
    Mason, W
    Mariani, L
    Bromberg, JEC
    Hau, P
    Mirimanoff, RO
    Cairncross, JG
    Janzer, RC
    Stupp, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (10) : 997 - 1003
  • [7] IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas
    Houillier, C.
    Wang, X.
    Kaloshi, G.
    Mokhtari, K.
    Guillevin, R.
    Laffaire, J.
    Paris, S.
    Boisselier, B.
    Idbaih, A.
    Laigle-Donadey, F.
    Hoang-Xuan, K.
    Sanson, M.
    Delattre, J. -Y.
    [J]. NEUROLOGY, 2010, 75 (17) : 1560 - 1566
  • [8] Phase II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults
    Kesari, Santosh
    Schiff, David
    Drappatz, Jan
    LaFrankie, Debra
    Doherty, Lisa
    Macklin, Eric A.
    Muzikansky, Alona
    Santagata, Sandro
    Ligon, Keith L.
    Norden, Andrew D.
    Ciampa, Abigail
    Bradshaw, Joanna
    Levy, Brenda
    Radakovic, Gospova
    Ramakrishna, Naren
    Black, Peter M.
    Wen, Patrick Y.
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (01) : 330 - 337
  • [9] Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study
    Klein, M
    Heimans, JJ
    Aaronson, NK
    van der Ploeg, HM
    Grit, J
    Muller, M
    Postma, TJ
    Mooij, JJ
    Boerman, RH
    Beute, GN
    Ossenkoppele, GJ
    van Imhoff, GW
    Dekker, AW
    Jolles, J
    Slotman, BJ
    Struikmans, H
    Taphoorn, MJB
    [J]. LANCET, 2002, 360 (9343) : 1361 - 1368
  • [10] Continuous growth of mean tumor diameter in a subset of grade II gliomas
    Mandonnet, E
    Delattre, JY
    Tanguy, ML
    Swanson, KR
    Carpentier, AF
    Duffau, H
    Cornu, P
    Van Effenterre, R
    Alvord, EC
    Capelle, L
    [J]. ANNALS OF NEUROLOGY, 2003, 53 (04) : 524 - 528
12